NCT04262375撤回2 期
A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Association between cfMeDIP and Response (defined as either complete response, partial response, or stable disease ≥ 4 cycles, as per RECIST 1.1. Association between cfMeDIP and Toxicity (defined as ≥ Grade 2 immune- adverse event (AE) as per CTCAE 5.0).
研究概览
简要总结
This is a Phase II, prospective, non-randomized, open-label trial involving cancer patients with known inflamed tumor types. Patients with previously treated advanced/metastatic non-small cell lung cancer or renal cell cancer will be recruited in near equal distribution. All patients must have documented response or prolonged stable disease to previous immunotherapy. At present, we plan to enrol 55 patients, to be treated with durvalumab and oleclumab. The regimen will consist of durvalumab 1500 mg given by vein every 4 weeks and oleclumab 3000 mg given by vein every 2 weeks x 4 doses then IV every 4 weeks till disease progression, withdrawal of subject consent, or another reason for discontinuation. Estimated total duration from time to first subjects consent to last subject's last visit is approximately 36 months.
详细描述
Study Hypotheses:
- Circulating free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) can yield cancer type-agnostic predictive biomarker(s) of response and/or toxicity in subjects receiving this combination.
- The combination of oleclumab (anti-cluster of differentiation [CD]73 monoclonal antibody) with durvalumab (anti programmed cell death ligand 1 [PD-L1]) will demonstrate adequate safety, tolerability, and antitumor activity in subjects with metastatic non-small-cell lung cancer (NSCLC) and renal cell cancer (RCC) previously treated with checkpoint inhibitors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years at the time of screening or age of consent according to law
- •Life expectancy of at least 12 weeks
- •Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- •ECOG 0 or 1
- •Weight ≥35kg
- •Subjects diagnosed with histologically or cytologically confirmed non small cell lung (NSCLC) or renal cell carcinoma (RCC)
- •Subjects must have at least 1 measurable lesion according to RECIST version 1.
- •Archival tumor formalin-fixed, paraffin-embedded (FFPE) specimens for correlative biomarker studies are required (1 H&E and 15 unstained slides). Subjects with insufficient archived tumor samples are still eligible, pending discussion with the principal investigator on a case by case basis
- •Adequate organ and marrow function
- •Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception from screening to 90 days after the final dose of study treatment
- •Nonsterilized male subjects who are sexually active with a female partner of childbearing potential must use a male condom with spermicide from screening to 90 days after receipt of the final dose of study treatment
排除标准
- •Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment
- •Prior receipt of any agents targeting CD73, including patients treated with adenosine receptor antagonists, CD39 or CD73 inhibitors
- •Prior receipt of any innate immune agonists
- •Patients with NSCLC with known activating EGFR mutations or ALK translocations
- •Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed
- •Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent
- •Subjects with a history of Grade 3 or greater thromboembolic events in the prior 12 months or thromboembolic event of any grade with ongoing symptoms
- •Subjects with prior history of myocardial infarction, transient ischemic attack, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment
- •Active or prior documented autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment
- •HIV, Hep A, B, or C
- •History of primary immunodeficiency, solid organ transplantation, or active tuberculosis
- •Known allergy or hypersensitivity to investigational product formulations
- •History of more than one event of infusion related reactions (IRR) requiring permanent discontinuation of IV drug treatment
- •Active grade 3 or greater edema
- •History of Grade 3 or greater thromboembolic events in the prior 12 months or thromboembolic event of any grade with ongoing symptoms
- •Uncontrolled intercurrent
- •Any history of untreated leptomeningeal disease or cord compression
- •Untreated CNS metastatic disease
- •Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment
- •Receipt of live, attenuated vaccine within 30 days prior to the scheduled first dose of study treatment
- •Major surgery within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery
- •Females who are pregnant, lactating, or intend to become pregnant during their participation in the study
- •Subjects who are involuntarily incarcerated or are unable to willingly provide consent or are unable to comply with the protocol procedures
- •Any condition that would interfere with the evaluation of the study regimen or interpretation of patient safety or study results
- •Any condition that would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results
结局指标
主要结局
Association between cfMeDIP and Response (defined as either complete response, partial response, or stable disease ≥ 4 cycles, as per RECIST 1.1. Association between cfMeDIP and Toxicity (defined as ≥ Grade 2 immune- adverse event (AE) as per CTCAE 5.0).
时间窗: 3 years
To identify cfMeDIP-seq-based predictive signature(s) that are correlated with specific outcome to durvalumab and oleclumab such as response/resistance or occurrence of toxicity in non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC)
Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
时间窗: 3 years
Disease control rate (DCR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
时间窗: 3 years
Duration of response (DoR)
时间窗: 3 years
次要结局
- Incidence of treatment-emergent adverse events (AEs)(3 years)
- Overall survival (OS) or progression-free survival (PFS)(3 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck CancerHead and Neck NeoplasmsMetastatic CancerHead and Neck CancerNCT03691714University of Cincinnati35
已完成
2 期
Phase 2 Study of Durvalumab (MEDI4736) in Patients With GlioblastomaGlioblastomaNCT02336165Ludwig Institute for Cancer Research159
终止
2 期
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY TrialMetastatic Thyroid Papillary CarcinomaMetastatic Thyroid Follicular CarcinomaMetastatic Thyroid CancerNCT03753919Grupo Espanol de Tumores Neuroendocrinos79
已完成
2 期
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract CancerBiliary Tract Cancer (CCA)Hilar CholangiocarcinomaDistal CholangiocarcinomaGall Bladder CarcinomaIntrahepatic CholangiocarcinomaNCT05239169Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest40
招募中
2 期
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLCExtensive-stage Small-cell Lung CancerNCT06223711Universität des Saarlandes43